1 friday, april 19 Biochemistry and Molecular Biology asbmb graduate and postdoctoral travel award keynote lecture special Session

S. R. Smith. Sanford-Burnham 

Med. Res. Inst.

WEDNESDAY PHARMACOLOGY

132

11:15 

5-HT2C receptor agonists: a mechanistically new target 

for type 2 diabetes treatment. 

L. Heisler. Univ. of 

Cambridge.

11:50  5HT2C receptor agonist anorectic efficacy potentiated 

by 5-HT1B receptor agonist co-application: an effect 

mediated via augmented pro-opiomelanocortin 

neuron activation.  

B. Doslikova. Univ. of Cambridge.

479.  SIR JAMES BLACK LECTURE

(Sponsored by: The British Pharmacological Society and 

ASPET)

W

eD

. 2:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 157aBC

The Sir James Black Lecture, sponsored jointly this year by 

the British Pharmacological Society and ASPET, is given to honor 

the eminent pharmacologist and Nobel Laureate, Sir James Black, 

who is credited with revolutionizing medical treatment through 

his discovery of the first beta-blocker drug, propranolol, and the 

first histamine antagonist, cimetidine. Dr. Robert Lefkowitz was 

selected because of the leading role he has played in garnering 

an understanding of the structure and function of G-Protein 

coupled receptors. 

Note: This lecture is part of the G-Protein Coupled Receptors 

Colloquium which continues Wednesday evening and Thursday. 

While this lecture is open to any EB registrant, attendance at 

the poster session, dinner, and remainder of the colloquium 

Wednesday evening and Thursday requires separate registration.

2:00 Introduction. 

H. Rang. British Pharmacol. Society.

2:05  Molecular mechanisms of biased agonism at 7 

transmembrane receptors. 

R. J. Lefkowitz. Duke 

Univ. Med. Ctr.

480.  BRIDGING THE EFFICACY DIVIDE: NOVEL 

MOLECULAR INSIGHTS DRIVING BIASED 

LIGAND DRUG DISCOVERY

Symposium

(Sponsored by: The British Pharmacological Society and 

the ASPET Divisions for Neuropharmacology; Molecular 

Pharmacology; Drug Discovery and Development; and 

Toxicology)

W

eD

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 157aBC

C

haired

: a. C

hristopoulos

 

anD

 r.J. l

eFKoWitz

Note: This session is part of the G-Protein Coupled Receptors 

Colloquium which continues Wednesday evening and Thursday. 

While this session is open to any EB registrant, attendance at 

the poster session, dinner, and remainder of the colloquium 

Wednesday evening and Thursday requires separate registration.

3:00  Biased ligands: developing better drugs through 

selective signaling at GPCRs. 

J. Violin. Tevana Inc.

3:35 

Ligand-biased signaling under the light of BRET. 

M. 

Bouvier. Univ. of Montreal.

4:10  Allosteric modulation of endogenous metabolites: 

implications for on- and off-target drug action and 

bias. 

P. M. Sexton. Monash Univ., Australia.

4:45 

Moving from biased signaling to functional (physiological) 

bias. 

A. Tobin. Univ. of Leicester.

5:20 

The atypical antipsychotic clozapine induces 5-HT2AR-

mediated signaling and behavioral events in a beta-

arrestin2-independent but Akt-dependent manner. 

C.L. Schmid, J.M. Streicher and L.M. Bohn. The 

Scripps Res. Inst. 

(1171.7)

481.  PERIPHERAL MECHANISMS OF OPIOID 

ANALGESIA

Symposium

(Sponsored by: The Divisions for Neuropharmacology; 

Behavioral Pharmacology; and Molecular Pharmacology)

W

eD

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 106

C

haired

: K.a. B

erG

3:00 

Current status of pain therapeutics. 

K. M. Hargreaves. 

Univ. of Texas Hlth. Sci. Ctr. at San Antonio.

3:35 

Molecular determinants and thermodynamics of opioid 

receptor signaling. 

M. Filizola. Mount Sinai Sch. of 

Med.

4:10 

6’GNTI is a G protein-biased kappa opioid receptor 

agonist that inhibits arrestin recruitment. 

J. A. Javitch. 

Columbia Univ. Med. Ctr.

4:45  DOR-KOR heteromer-mediated signaling and 

antinociception in primary sensory neurons. 

W. P. 

Clarke. Univ. of Texas Hlth. Sci. Ctr. at San Antonio.

5:20 Discussion.

482.  SLEEP APNEA: A SLEEPING GIANT IN 

DISEASE PATHOLOGIES

Symposium

(Sponsored by: The Divisions for Integrative Systems, 

Translational and Clinical Pharmacology; Behavioral 

Pharmacology; Cardiovascular Pharmacology; and 

Neuropharmacology)

W

eD

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107B

C

haired

: i. l

aher

 

anD

 n. a

yas

3:00 

Sleep apnea for non-experts. 

N. Ayas. Univ. of British 

Columbia.

3:30 

Animal models of sleep apnea. 

V. Polotsky. Johns 

Hopkins Univ.

4:00 

Sleep apnea as a risk factor for cardiovascular diseases. 

T. D. Bradley. Univ. of Toronto.

4:30 

Sleep apnea and type 2 diabetes. 

E. Tasali. Univ. of 

Chicago Med. Ctr.

5:00 

Biomarkers in sleep apnea. 

A. Malhotra. Brigham and 

Women’s Hosp., Harvard Med. Sch.

PHARMACOLOGY WEDNESDAY

133

W

E

D

483.  STEM CELLS: PHARMACOLOGY AND 

THERAPEUTICS

Symposium

(Sponsored by: The British Pharmacological Society-

Young Scientists and the ASPET Divisions for Integrative 

Systems, Translational and Clinical Pharmacology; and 

Behavioral Pharmacology)

W

eD

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 108

C

haired

: D. r

eeD

 

anD

 J.a. m

itChell

3:00 

Introduction to stem cells in pharmacology. 

D. Reed. 

Imperial Col. London.

3:10 

Langer Lab research: microfluidics and hESC research. 

A. Sharei and J. Zolden. MIT.

3:45 

Bioinformatic analysis of microglia-neural stem cell 

interactions: a role for wnt5a? 

M. Woodbury, K. 

Ingraham, R. Freilich and T. Ikezu. Boston Univ. Sch. 

of Med. 

(1181.5)

3:55 

Stem cells as a platform for biotherapeutic drug safety 

screening. 

J. A. Mitchell. Imperial Col. London.

4:25  Cell-Based solutions for cardiovascular disease. 

D.Taylor. Texas Health Inst.

5:00 

Stem cells: the future of therapy for pulmonary 

hypertension. 

D. J. Stewart. Ottawa Hosp. Res. Inst.

484.  SYSTEMS BIOLOGY ANSWERING 

PHARMACOLOGICAL QUESTIONS

Symposium

(Sponsored by: The Divisions for Toxicology and Integrative 

Systems, Translational and Clinical Pharmacology)

W

eD

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109a

C

haired

: r. n

euBiG

 

anD

 J. l

azo

3:00 

P4 medicine: how a systems approach will revolutionize 

medicine. 

L. Hood. Inst. for Systems Biol.

3:45 

Network models in cancer pharmacology. 

D. Pe’er. 

Columbia Univ.

4:20  Practical applications of systems biology in the 

pharmaceutical industry. 

B. Gomes. Novartis Insts. 

for BioMed. Res.

4:55 

Metabolic network analysis to predict therapeutic 

responses. 

J. Papin. Univ. of Virginia.

485.  ASPET CLOSING RECEPTION

Special Event

W

eD

. 6:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 

B

allroom

 F

oyer

Physiology

APS President’s Symposium Series

From Animals to Human Models of Disease

486

.  NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE 

LECTURE

W

eD

. 4:45 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 210BC

Translational Physiology

Title:  Unraveling Smell 

Speake

r: L. Buck. Fred Hutchinson Cancer Res. Ctr.

487

.  ASSEMBLY AND TRAFFICKING TO THE 

INTESTINAL BRUSH BORDER

Symposium

(Sponsored by: APS Gastrointestinal and Liver 

Physiology Section)

W

eD

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 208

C

haired

: J. r. G

olDenrinG

8:00 

A role for protocadherins in the cross-linking and 

assembly of apical microvilli. 

M. Tyska. Vanderbilt 

Univ.

8:30 

Role of Cdc42 in apical trafficking and microvillus 

morphogenesis. 

N. Gao. Rutgers Univ.

9:00 

Role of myosin Vb and Rabs in assembly of the brush 

border microvilli. 

J. R. Goldenring. Vanderbilt Univ.

9:30 

Acute regulation of NHE3 occurs via separate control of 

trafficking and microvillar cytoskeletal association. 

M. 

Donowitz. Johns Hopkins Univ.

488

.  BRAIN STRAIN: CHALLENGES TO CEREBRAL 

BLOOD FLOW REGULATION IN HUMANS

Featured Topic

(Sponsored by: APS Environmental and Exercise 

Physiology Section)

W

eD

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 206a

C

haired

: C. a. r

iCKarDs

 

anD

 J. m. s

erraDor

8:00 Introduction. 

J. M. Serrador. Brigham and Women’s 

Hosp., Harvard Med. Sch.

8:05 

New concepts in the regulation of cerebral blood flow. 

S. 

Tzeng. Univ. of Otago, New Zealand.

8:25 

Sex differences in age-related changes in cerebral 

vasodilator responses. 

J.N. Barnes, J.L. Taylor, W.T. 

Nicholson and M.J. Joyner. Mayo Clin. (1203.11)

8:40 

Improvement of hypovolemic men’s and women’s 

orthostatic tolerance by a short exposure to artificial 

gravity. 

J.M. Evans, L.C. Ribeiro, S. Wang, M.J. 

Falvo, J. Serrador, C.R. Ferguson, F.B. Moore, 

J.D. Smith, J.C. Rask, V. Kostas, Q. Zhang and 

C.F. Knapp. Univ. of Kentucky, WyleST&E, Houston, 

VA New Jersey Healthcare, East Orange and NASA 

Ames Res. Ctr., CA. 

(1203.2)

WEDNESDAY PHARMACOLOGY/PHYSIOLOGY 

134

8:55 

Changes in cerebral scattering and hemodynamics 

associated with acute mountain sickness. 

D.M. 

DiPasquale, Z. Li, S.R. Muza and G.E. Strangman. 

Massachusetts Gen. Hosp., Charlestown, Harvard 

Med. Sch. and U.S. Army Res. Inst. of Envrn. Med., 

Natick, MA. 

(1203.9)

9:10 

Metabolic syndrome alters the balance of prostaglandins 

in hypoxia-mediated cerebral vasodilation. 

J.W. 

Harrell, P.A. Yanke and W.G. Schrage. Sch. of Med. 

and Publ. Hlth., Univ. of Wisconsin-Madison. 

(1203.10)

9:25 

Association between cerebral tissue structural integrity 

and dynamic cerebral autoregulation in elderly 

individuals. 

S. Purkayastha, O. Fadar, A. Mehregan, 

L.A. Lipsitz and F.A. Sorond. Hebrew SeniorLife, 

Boston, Harvard Med. Sch. and Brigham and Women’s 

Hosp. 

(1203.12)

9:40  Cerebral blood flow regulation during central 

hypovolemia. 

C. A. Rickards. Univ. of North Texas 

Hlth. Sci. Ctr.

489

.  CROSSTALK BETWEEN 1-CARBON 

METABOLISM AND PATHWAYS ASSOCIATED 

WITH METABOLIC DISEASES

Featured Topic

(Sponsored by: APS Endocrinology and Metabolism Section)

W

eD

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 207

C

haired

: l. W

anG

Metabolic Diseases

8:00 

Choline metabolism in mitochondrial function and 

insulin sensitivity. 

S. H. Zeisel. Univ. of North Carolina, 

Kannapolis.

8:30 

Nuclear receptor regulation of one carbon metabolism 

associated with metabolic disease. 

L. Wang. Univ. of 

Utah Sch. of Med.

9:00 

Body-on-a-chip BOAC: a tool to elucidate clinical 

observations that involve modulations of the 

“ethylation pathway in association with the expression 

of adipokines. 

M. Ariza-Nieto, J.B. Alley, S.A. Samy, 

L. Fitzgerald and M.L. Shuler. Cornell Univ. and 

Guthrie Clin., Sayre, PA. 

(1153.13)

9:15 

A novel Mito-Timer reporter gene for measurement of 

mitochondrial quantity and quality in vivo. 

R.C. Laker, 

P. Xu, K. Ryall, A. Sujkowski, M. Zhang, P. Adler, R. 

Wessells, J. Saucerman and Z. Yan. Univ. of Virginia 

and Univ. of Michigan. 

(1209.5)

9:30 

The role of suppressor enhancer lin-12 1 like in 

cholesterol metabolism. 

C. Krumm, A. Francisco, 

W-H. Chang and Q. Long. Cornell Univ. (1208.10)

9:45  Phosphorylation of rat skeletal muscle pyruvate 

dehydrogenase phosphatase in response to insulin 

stimulation. 

J. Choptiany, R. MacPherson, P. LeBlanc 

and S. Peters. Brock Univ., Canada. (1208.1)

490.  MICRORNA AND STEM CELL IN MUSCLE 

PATHOPHYSIOLOGY

Featured Topic

(Sponsored by: APS Muscle Biology Group)

W

eD

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 209

C

haired

: p. m

ishra

 

anD

 p. a

nversa

8:00 

Role of cardiac stem cell in cardiac pathophysiology. 

P. 

Anversa. Brigham and Women’s Hosp.

8:30 

microRNA in cardioprotection. 

R. C. Kukreja. Virginia 

Commonwealth Univ.

9:00 

miR-133a ameliorates cardiac stem cells survival and 

differentiation in Insulin2 mutant diabetic mice. 

V. 

Chavali, N.L. Diaz, S.C. Tyagi and P.K. Mishra. Univ. 

of Louisville. 

(1151.2)

9:15  Mitochondrial division inhibitor ameliorates post-

myocardial infarction via stimulating stem cell by 

elevating level of miR-499 in diabetes. 

N. Qipshidze, 

P.K. Mishra and S.C. Tyagi. Univ. of Louisville. 

(1151.1)

9:30 

Ablation of MMP9 ameliorates epigenetic modifications 

and mitigates diabetic cardiomyopathy. 

P.K. Mishra, 

V. Chavali, N. Metreveli and S.C. Tyagi. Univ. of 

Louisville. 

(1129.3)

9:45 

General discussion.

491.  NCAR TRAINEE FEATURED TOPIC

Featured Topic

(Sponsored by: APS Neural Control and Autonomic 

Regulation Section)

W

eD

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 211

C

haired

: e. l

azartiGues

 

anD

 p. s

hi

8:00  Acute prorenin infusion mediates angiotensin II-

dependent pressor response via binding to (pro)

renin receptor in the central nervous system. 

W. Li, 

H. Peng, A. Ichihara and Y. Feng. Tulane Univ. and 

Tokyo Women’s Med. Univ. 

(927.1)

8:15 

Central sympathoinhibition ameliorates the reduction 

of splenic regulatory T cells with decreased IL-

17 production in hypertensive rats. 

M.  Katsuki, Y. 

Hirooka, T. Kishi and K. Sunagawa. Kyushu Univ. 

Grad. Sch. of Med. Sci., Japan. 

(927.2)

8:30  Unilateral renal denervation improves autonomic 

balance in conscious rabbits with chronic heart failure. 

A. Schiller, K. Haack, P. Curry and I. Zucker. Univ. of 

Nebraska Med. Ctr. 

(927.16)

8:45 

Brain targeted ACE2 overexpression prevents DOCA-

salt hypertension and cardiac hypertrophy by 

modulating NOS and ERK1/2 phosphorylation. 

S. 

Sriramula, H. Xia and E. Lazartigues. LSU Hlth. Sci. 

Ctr.-New Orleans. 

(927.7)

9:00 

Central neural mechanisms underpinning amplified 

respiratory-sympathetic coupling in the spontaneously 

hypertensive rat. 

D.J.A. Moraes, B.H. Machado and 

J.F.R. Paton. Univ. of São Paulo, Ribeirão Preto and 

Univ. of Bristol. 

(927.12)

PHYSIOLOGY WEDNESDAY

135

W

E

D

9:15 

Increased expression of AT2 receptors in the nucleus 

of the solitary tract improves baroreflex function in 

renovascular hypertensive rats. 

G.T. Blanch, A.H. 

Freiria-Oliveira, K. Rigatto, H. Li, E. Colombari, C. 

Sumners and D.S.A. Colombari. Fac. of Odontol., 

São Paulo State Univ., Araraquara, Fed. Univ. of 

Hlth. Sci., Porto Alegre, Brazil, Sch. of Biotechnol., 

Southern Med. Univ., China and Univ. of Florida. 

(927.10)

9:30  Does endothelial peroxisome proliferator-activated 

receptor gamma protect baroreflex function during 

obesity? 

B.H. McCully, K.D. Duffy, C.D. Sigmund 

and V.L. Brooks. Oregon Hlth. & Sci. Univ. and Univ. 

of Iowa. 

(927.11)

9:45 

Aldosterone acts in the nucleus tractus solitarius to 

increase expression of vasopressin (AVP) in the 

paraventricular nucleus of the hypothalamus. 

N. Cho 

and D. Scheuer. Univ. of Florida. (927.15)

492.  NEUROTROPHINS IN THE RESPIRATORY 

SYSTEM

Symposium

(Sponsored by: APS Respiration Section)

W

eD

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 210a

C

haired

: y. s. p

raKash

 

anD

 G. C. s

ieCK

8:00 

Brain-derived neurotrophic factor in the developing 

airway. 

R. J. Martin. Case Western Reserve Univ.

8:25 

Nerve growth factor in epithelial responses to viral 

infections in neonates. 

G. Piedimonte. West Virginia 

Univ.

8:50 

Neurotrophins and GDNF in vagal innervation of the 

respiratory tract. 

B. J. Undem. Johns Hopkins Univ.

9:15 

Autocrine/paracrine effects of brain-derived neurotrophic 

factor in human airways, and their role in asthma. 

Y. S. 

Prakash. Mayo Clin.

9:40 

Neurotrophin regulation of diaphragmatic function: from 

development through aging. 

C. Mantilla. Mayo Clin.

493.  THE ROLE OF PSYCHOLOGICAL STRESS 

AND DEPRESSION IN DETERMINING 

CARDIOVASCULAR DISEASE RISK: THE 

USE OF ANIMAL MODELS AND CLINICAL 

APPLICATION

Symposium

(Sponsored by: APS Cardiovascular Section)

W

eD

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 205C

C

haired

: p. m

arvar

 

anD

 a. G

rippo